Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma, has launched Pomalidomide Capsules, 1 mg, 2 mg, 3 mg and 4 mg, in the US market. The product is the generic equivalent of Pomalyst® Capsules, 1 mg, 2 mg, 3 mg and 4 mg, of BMS Pharmaceuticals Corp.
Eugia Pharma Specialities was one of the First-to-File (FTF) ANDA applicants for this product. The product will be manufactured at Eugia Unit-I.
According to IQVIA MAT data for the twelve months ending January 2026, Pomalidomide Capsules have an estimated market size of approximately US$ 3.3 billion in the U.S.
Pomalidomide is a third-generation immunomodulatory drug (IMiD) used in combination with dexamethasone (and sometimes bortezomib) to treat relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma.
Pomalidomide, a third-generation immunomodulatory drug (IMiD), is used in combination with dexamethasone, and sometimes bortezomib, for relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma.
Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services.
The company’s consolidated net profit rose 7.6% to Rs 910.29 crore on a 9% increase in net sales to Rs 8,604.51 crore in Q3 FY26 over Q3 FY25.
Shares of Aurobindo Pharma shed 0.95% to Rs 1,199.85 on the BSE.
The company confirmed there is no impact on its financials or operations due to the inspection. Aurobindo Pharma stated its commitment to maintaining high-quality manufacturing standards across all its facilities worldwide and said it will update the stock exchanges if there is any further information.
Shares of Aurobindo Pharma shed 0.04% to end at Rs 1,221.55 on the BSE on Friday.
Aurobindo Pharma announced that its wholly owned subsidiary, Eugia Pharma Specialities, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Everolimus Tablets, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Zortress Tablets, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, of Novartis Pharmaceuticals Corp.
This approval has been received from Eugia Unit-I and is expected to be launched in Q1FY27.
The approved product has an estimated market size of US$ 78 million for the twelve months ending December 2025, according to IQVIA MAT.
This is the 184th ANDA approval (including 10 tentative approvals received) out of Eugia Pharma Specialities Group (EPSG) facilities, manufacturing both oncology oral and sterile specialty products.
Everolimus Tablets are Indicated for the prophylaxis of organ rejection in adult patients (i) Kidney Transplant: at low-moderate immunologic risk. Use in combination with basiliximab, cyclosporine (reduced doses) and corticosteroids (ii) Liver Transplant: Administer no earlier than 30 days posttransplant. Use in combination with tacrolimus (reduced doses) and corticosteroids.
Everolimus tablets are indicated for the prophylaxis of organ rejection in adult patients undergoing kidney and liver transplants. For kidney transplant patients at low-to-moderate immunologic risk, the drug is used in combination with basiliximab, reduced-dose cyclosporine and corticosteroids. For liver transplant patients, it is administered no earlier than 30 days post-transplant, in combination with reduced-dose tacrolimus and corticosteroids.
The approval was granted to Eugia Unit-I, and the product is expected to be launched in the first quarter of FY27. According to IQVIA MAT data for the twelve months ended December 2025, the approved product has an estimated market size of $ 78 million.
With this approval, Eugia Pharma Specialities Group has received a total of 184 ANDA approvals, including 10 tentative approvals, across its facilities manufacturing oncology oral and sterile specialty products.
Aurobindo Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 1225.5, up 1.16% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.12% on the day, quoting at 25452.6. The Sensex is at 82117.03, down 0.19%. Aurobindo Pharma Ltd has risen around 8.48% in last one month.
Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has risen around 6.36% in last one month and is currently quoting at 23051.85, up 0.53% on the day. The volume in the stock stood at 14.57 lakh shares today, compared to the daily average of 22.48 lakh shares in last one month.
The benchmark March futures contract for the stock is quoting at Rs 1229.4, up 0.67% on the day. Aurobindo Pharma Ltd is up 13.4% in last one year as compared to a 12.9% spurt in NIFTY and a 14.71% spurt in the Nifty Pharma index.
The PE of the stock is 32.89 based on TTM earnings ending December 25.